Exploiting Precision Oncology to Treat Virally Driven Cancer

Viracta is a precision oncology company treating virally associated cancers. By targeting the viral genome to kill the cancer, Viracta exploits a precision therapy that is both more effective and less toxic.

The Company's proprietary investigational drug, Natinostat, induces expression of EBV genes, that in combination with antiviral valganciclovir, leads to cancer cell death and is being tested as a therapy for EBV-positive lymphoma and solid tumors, showing promising early clinical data.